MD安德森新闻稿04 \/ 16 \/ 2015
癌症的科学家杰姆斯埃里森博士，国际知名的他在开发一种新的癌症免疫疗法类的作用，被称为癌症研究者2015 pezcoller基础的美国协会（AACR）国际癌症研究奖。该奖项将颁发给埃里森，在2015届AACR年会，是在费城举行，四月18-22。
埃里森，在德克萨斯大学MD安德森癌症中心免疫学的椅子，被承认为他的突破性发现，阻断细胞毒性T淋巴细胞相关抗原4（CTLA-4）信号，提高了抗肿瘤的免疫反应，以及他在发展CTLA-4抑制剂ipilimumab（Yervoy）的作用，这是一个新的癌症免疫疗法班称为免疫检查点抑制剂。Ipilimumab，这是批准用于治疗转移性黑色素瘤由美国食品和药物管理局在2011，是第一个以改善这种致命的癌症患者生存率的治疗。
埃里森杰姆斯，博士
在MD安德森，埃里森也作为MD安德森登月计划的免疫学平台执行主任的癌症免疫研究中心副主任的戴维H。科赫应用研究中心泌尿生殖系统癌症的副主任，和丽莲H。史密斯特聘免疫学及董事学会委员会成员。他还担任副总编辑肿瘤免疫学研究和科学编辑癌症发现。
The Pezcoller Foundation-AACR International Award, now in its 18th year, recognizes an individual scientist of international renown who has made a major scientific discovery in basic or translational cancer research。
“This high honor is yet further recognition of the pioneering work undertaken by Dr。 Allison,” said Ronald DePinho, M。D, president of MD Anderson。 “He is, without question, one of the leading cancer researchers in the world today and has made historic contributions to advances in cancer treatment。 We are immensely proud of his achievements and congratulate him on being named this year’s Pezcoller Award recipient。”
Allison’s research into the molecular mechanisms of activating the T-cell receptor and the downstream signal transduction events that affect immune function led to his finding that CTLA-4 is an immune system inhibitory checkpoint molecule expressed by T cells。 His lab then developed an antibody against CTLA-4, which they went on to show inhibited tumor growth in mice。
This basic research discovery led to the development of ipilimumab。 By specifically blocking the inhibitor function of CTLA-4, ipilimumab allows T cells to attack and eliminate cancer cells。 Allison called this action mechanism “immune checkpoint blockade。” He believes that by combining targeted therapies with immunotherapeutics that mediate checkpoint blockade, one can turn cancer’s genomic instability, which it uses to build resistance to drugs, against it。 Allison is currently investigating additional mechanisms involved in T-cell activation and signaling pathways。
“Dr。 Allison is a world-renowned immunologist, and we are delighted to recognize his extraordinary scientific accomplishments and leadership in the field of cancer immunotherapy,” said Margaret Foti, Ph。D。, M。D, chief executive officer of the AACR。 “His dedicated efforts established the paradigm of immune checkpoint inhibitors, which is transforming the lives of many patients with melanoma and offering hope for patients with other forms of cancer。 Dr。 Allison’s work epitomizes how basic laboratory research can be translated to a lifesaving cancer treatment, and he is greatly deserving of this accolade。”
“I am deeply honored and humbled to receive the Pezcoller Award,” said Allison。 “This award by the AACR recognizes the efforts of my research team over the years to develop strategies to unleash the immune system to treat cancer, as well as the many other investigators, clinicians, and patients whose efforts and courage made immunotherapy of cancer a reality that is benefiting cancer patients。”
Allison is a member of the National Academy of Sciences and is a fellow of the Institute of Medicine, the American Association for the Advancement of Sciences, and the American Academy of Microbiology。
其他荣誉包括：
• 突破奖生命科学
• Szent-Györgyi奖从国家 癌症研究进展
癌症研究基金会
• 第一堂生物医药科学奖
美国免疫学家协会 • 终身成就奖
• Centeon奖免疫学中的创新突破，并
• the William B。 Coley Award for Distinguished Research in Basic and Tumor
生物学肿瘤研究所
He received the inaugural AACR-Cancer Research Institute Lloyd J。 Old Award in Cancer Immunology, the AACR-G。H。A。 Clowes Memorial Award, the Canada Gairdner Foundation award, and leads the Stand Up To Cancer-Cancer Research Institute Dream Team: Immunologic Checkpoint Blockade and Adoptive Cell Transfer in Cancer Therapy。
（注：转载时请注明复诊网）
